Carcinoma of the oral pharynx: an analysis of subsite treatment heterogeneity.
The data indicate that SCC of the various subsites of the oropharynx can be treated successfully with acceptable locoregional control and survival rates by using either surgery or primary radiotherapy for TI or T2 primary lesions. Treatment success data for late-stage disease (T3 and T4) are less encouraging. regardless of which modality is used or which treatment center is administering treatment. This finding may suggest an intrinsic property of these lesions or the patient that may be going unnoticed.One problem is that the diversity of approaches to these lesions hinders any meaningful comparisons between series from different treatment centers. There exists heterogeneity in patient populations and approaches to staging and characterization of these diseases. This situation has ensured the same heterogeneity in treatment philosophy, which is largely institutionally based.
Osborne
Ryan F
RF
Department of Otolaryngology-Head and Neck Surgery, Charles R. Drew University of Science and Medicine, 12021 South Wilmington Avenue, Room 5004, Los Angeles, CA 90059-3051, USA.
Brown
Jimmy J
JJ
D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D003131:Combined Modality Therapy; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D006801:Humans; D008207:Lymphatic Metastasis; D009062:Mouth Neoplasms / Q000473:pathology / Q000628:therapy; D010157:Palatal Neoplasms / Q000473:pathology / Q000628:therapy; D010160:Palate, Soft / Q000473:pathology; D010610:Pharyngeal Neoplasms / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D014062:Tongue Neoplasms / Q000473:pathology / Q000628:therapy; D014067:Tonsillar Neoplasms / Q000473:pathology / Q000628:therapy